Immutep Ltd IMMP:NASDAQ

RT Quote | USD
Last | 03/27/24 EDT
2.39UNCH (UNCH)
Volume
87,398
52 week range
1.50 - 3.90
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.39
  • 52 Week High3.90
  • 52 Week High Date05/17/23
  • 52 Week Low1.50
  • 52 Week Low Date05/15/23

Key Stats

  • Market Cap293.64M
  • Shares Out118.88M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta2.14
  • YTD % Change-0.42

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close2.39
  • 52 Week High3.90
  • 52 Week High Date05/17/23
  • 52 Week Low1.50
  • 52 Week Low Date05/15/23
  • Market Cap293.64M
  • Shares Out118.88M
  • 10 Day Average Volume0.11M
  • Dividend-
  • Dividend Yield-
  • Beta2.14
  • YTD % Change-0.42

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Immutep Ltd

 

Profile

MORE
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an...
Russell Howard Ph.D.
Independent Non-Executive Chairman of the Board
Marc Voigt
Chief Executive Officer, Executive Director
Deanne Miller
Chief Operating Officer, General Counsel, Joint Company Secretary
Address
Plaza Building, L 12 95 Pitt St
Sydney, NSW
NSW 2000
Australia